Avsnitt
-
Linda Hasadsri, M.D., Ph.D., and Huong T. Cabral, M.S., C.G.C., explain how Mayo Clinic Laboratories' targeted test panel facilitates accurate diagnosis of hereditary pancreatitis, which heightens the risk for pancreatic cancer. Test results can guide cancer monitoring for patients and their families.
(00:33)
Dr. Hasadsri, can you tell the audience a little bit about yourself and your background?(01:32)
And Ms. Cabral?(02:03)
Can you please give the audience a brief overview of this assay?(03:33)
Which patients should have this testing and when should it be performed?(04:23)
What alternative test options are available and how do these compare to our hereditary pancreatitis test?(08:48)
How are results used in patient care? -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss important industry updates and legislative insights gathered from Dr. Morice’s recent trip to Washington, D.C.
Their discussion includes:
The status of current laboratory-related legislative efforts, including the Protecting Access to Medicare Act (PAMA), the Saving Access to Laboratory Services Act (SALSA), and the Pandemic and All Hazards Preparedness Act (PAHPA).Current issues facing the laboratory industry, including prior authorization, coding, and potential FDA oversight of laboratory-developed tests.The importance of advocating on behalf of laboratories, clinicians, and patients, and engagement opportunities through professional societies like the College of American Pathologists and the American Clinical Laboratory Association. -
Saknas det avsnitt?
-
Wei Shen, Ph.D., and Rhianna Urban, M.S., CGC, explain how Mayo Clinic Laboratories' gene panel establishes a diagnosis of Lynch syndrome, which heightens the risk for several cancers. Test results can guide cancer surveillance for patients and their families.
(00:32)
Would each of you share a little bit about yourselves and your background? Dr. Shen?(01:25)
Rihanna, could we have you give a little background about yourself as well?(01:48)
Could you provide us with an overview of Lynch syndrome?(03:44)
Can you expand on why genetic testing for Lynch syndrome is so important?(06:03)
Who would benefit from Lynch testing?(07:51)
Is Lynch syndrome the only type of inherited predisposition to colon cancer?(08:48)
Does the healthcare provider order these tests, and what kind of samples should be considered in these patients?(10:50)
Are there any limitations to the types of variants that can be detected by this test? And how does Mayo Clinic Laboratories ensure comprehensive results for patients?
(14:24)
How are the results used in patient care?(16:33)
Could you summarize the benefits of these tests and of doing them at Mayo Clinic Laboratories? -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Elitza Theel, Ph.D., director of the Infectious Diseases Serology Laboratory at Mayo Clinic, to follow up on the syphilis epidemic and discuss updated testing recommendations.
Specific topics of discussion include:
Background information on syphilis and the epidemic occurring in the United States.The report recently published by the Centers for Disease Control and Prevention (CDC) with updated laboratory recommendations for syphilis testing.The different testing methods used to diagnose syphilis. -
Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' nicotine testing benefits patients in substance-use cessation programs and other settings. The serum and urine tests quantify nicotine and various metabolites.
(00:32)
Can you tell us a little bit about yourself and your background?(01:42)
Can you please provide an overview of substance use disorders, specifically nicotine dependence, and Mayo Clinic's nicotine testing options?(04:33)
Which patients should have this testing and when should it be performed?(05:54)
What alternative test options are available and how do these compare?
(06:40)
How are the results used in patient care? -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the Food and Drug Administration’s (FDA) progress on making a final rule around regulating laboratory-developed tests (LDTs).
Their discussion includes:
How the FDA’s proposed rule on regulating LDTs has advanced to the White House Office of Management and Budget (OMB) for review, and what to expect in the coming months.Ongoing work around the Saving Access to Laboratory Services Act (SALSA).How laboratorians and pathologists can stay engaged on these important issues. -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to honor Black History Month. They reflect on important advancements in healthcare and laboratory medicine that were led by Black healthcare professionals and scholars. They also discuss health inequities that impact communities throughout the United States.
Their discussion includes:
A few of the major advancements in the medical field made by Black scholars, nurses, doctors, and surgeons, and important contributions to laboratory medicine by pioneering Black physicians and physician-scientists.Health inequities, accessibility issues, and diseases that are more prevalent in African Americans and people of lower socioeconomic status.How misinformation impacts preventive health measures. -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Stefan Grebe, M.D., Ph.D., co-director of the Clinical Mass Spectrometry and Test Development Laboratory in the Department of Laboratory Medicine and Pathology, and Irina Bancos, M.D.,consultant in the Division of Endocrinology, Diabetes, and Metabolism with a joint appointment in biochemistry and immunology. They discuss the diagnosis and management of adrenal gland tumors.
Specific topics of discussion include:
How the adrenal glands function and how tumors may affect these small, hormone-producing glands.Testing options for diagnosing malignant and benign tumors of the adrenal gland.Mayo Clinic’s use of machine learning and other innovative tools to distinguish adrenal carcinoma from common benign adrenal tumors as well as non-endocrine adrenal malignancies. -
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' test panel provides comprehensive evaluation of patients with suspected monogenic early onset inflammatory bowel disease, or IBD. Accurate diagnosis is key to guiding therapy for patients, who might be as young as age 2.
(00:32)
Could you please tell us a little bit about your background?(01:17)
Could you please do a brief overview of our EOIBD test?(03:24)
Which patients should have this testing and when should it be performed?(05:31)
How are results used in patient care?(07:02)
What alternative test options are available and how do these compare to our test? -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss current activity of infectious diseases.
Their discussion includes:
Vector-borne diseases that are causing public health concerns, and the multi-agency public health strategy recently released by the U.S. Department of Health and Human Services to address the growing problem.The benefits of a public-private, collaborative approach to public health, and why laboratorians need to be involved.Both new and reemerging diseases that are being found across the United States, and how laboratory-developed tests play a vital role in diagnosing and managing these diseases. -
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.
(00:32)
Could you please provide a little information about your background?(02:09)
Please give a brief overview of the new test panels.(05:35)
Which patients should have this testing and when should it be performed?(09:49)
What alternative test options are available, and how do those compare to our testing at Mayo Clinic Laboratories?(13:15)
How are the results used in patient care? -
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.
(00:32)
Could you provide us with a little bit about yourself and your background?(02:56)
Would you elaborate on the role of you and the Mayo Clinic team in advancing insights with the use of mass spectrometry and its initial launch?(05:38)
Please share about Quantitative MASS-FIX and its specificity, and which patients should have this testing and when it should be performed.(09:42)
Is this a more simplified ordering menu?(15:01)
Would you elaborate on how this assay supports the IMWG guidelines?(16:01)
Are there any closing remarks you would like to add? -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss what companies in the healthcare and diagnostics industries are focusing on in 2024.
Their discussion includes:
Insights from the J.P. Morgan Healthcare Conference, and where investments are happening in the diagnostics industry.Observations from visiting Southeast Asia around international healthcare innovation and testing accessibility. The importance of private-public partnerships and investments to advance global health. -
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique blood test identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal health.
Speaker 3: (00:32)
Can you share a little about yourself and your background?Speaker 3: (01:00)
Can you provide us with an overview of this new preeclampsia assay?Speaker 3: (02:33)
Can you share what will be reported with this assay?Speaker 3: (03:07)
Which patients should have this testing and at what point should it be performed?Speaker 3: (03:35)
Can you share what alternative test options are available today for preeclampsia?Speaker 3: (03:52)
How are the test results used in patient care? -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Elitza Theel, Ph.D., director of the Infectious Diseases Serology Laboratory at Mayo Clinic, to talk about the sexually-transmitted disease syphilis.
Specific topics of discussion include:
The history, cause, and symptoms of syphilis.A rare recent outbreak of ocular syphilis cases.The dramatic rise in syphilis and congenital syphilis cases in the United States over the last few years.The variety of syphilis testing options. -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to welcome the new year and discuss the increase of respiratory viruses.
Their discussion includes:
The increasing number of COVID-19 and influenza cases across the United States.The endemic state of COVID-19 and tools for prevention.The continued need to protect public health and advocate for the reauthorization of the Pandemic and All-Hazards Preparedness Act. -
Jeff Meeusen, Ph.D., explains how Mayo Clinic Laboratories' new MI-Heart Ceramides assay helps guide the management of patients with mildly to moderately high cholesterol. The test measures levels of lipids beyond cholesterol that boost cardiovascular risk.
Show notes
(00:31)
Could you provide us a little bit about your background?(01:20)
Could you give us a brief overview of this assay?(02:45)
What patients should have this test and when should it be performed?(04:25)
Could you talk a little bit about alternative test options and how they compare to our ceramides test?(05:58)
Can you go a little bit further into how these results can impact patient care and how you may monitor patients in the future with this testing? -
Robin Patel, M.D., explains how a new Mayo Clinic Laboratories' assay can identify central nervous system pathogens that standard tests fail to detect. Rapid, precise diagnosis is essential to preventing long-term effects from these infections.
Show notes
Speaker 3: (00:32)
Please give us a brief introduction of yourself and your role at Mayo Clinic.Speaker 3: (01:44)
Could you please expand a bit on this newly developed sequencing assay — which is a shotgun metagenomic test on CSF — and explain how it's different from other sequencing methods?Speaker 3: (02:43)
Could you tell us more about the specific group of patients this test would be used for and how a provider might identify those patients? When during the care process should this be ordered?Speaker 3: (04:12)
Could you talk about the alternative test options and how they compare?Speaker 3: (05:42)
How are the results used in patient care? -
Linnea Baudhuin, Ph.D., and Kate Kotzer, M.S., CGC, describe how Mayo Clinic Laboratories' postmortem genetic tests can provide answers after a sudden unexplained cardiac death. Test results are important for managing family members' risk for cardiovascular disease.
Show notes
(00:32)
Would each of you share a little bit about yourselves and your backgrounds?(01:13)
Could you provide us with an overview of these new tests?(02:31)
Can you expand on why these postmortem cardiac tests are so important?(04:09)
Who could benefit from postmortem cardiac testing?(05:23)
How does a health care provider order these tests? What sample types are accepted?(07:09)
Is there a limit to the age of the specimen? Are there any limitations to the type of variants that can be detected by this test?(09:07)
What other unique features set these tests apart?(10:17)
How are the test results used in patient care?(11:22)
Could you summarize the benefits of doing these tests at Mayo? -
Devin Oglesbee, Ph.D., explains how Mayo Clinic Laboratories' cholestasis gene panel identifies mutations that cause low flow of bile from the liver. Test results help guide treatment decisions that can prevent liver damage.
Show notes
(00:32)
Could you please provide us a little information about your background?(01:46)
Could you please give the audience a brief overview of this assay?(03:45)
Which patients should have this testing and when should it be performed?(06:39)
How are the results used in patient care?(08:51)
What alternative test options are available and how do they compare to our test? - Visa fler